Zevra Therapeutics Inc (ZVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Sales | 20,401 | 12,043 | 3,695 | 4,449 | 3,425 |
| Cost of Goods | 1,345 | 1,366 | 2,303 | 3,573 | 175 |
| Gross Profit | 19,056 | 10,677 | 1,392 | 876 | 3,250 |
| Operating Expenses | 24,763 | 26,459 | 29,001 | 25,244 | 23,911 |
| Operating Income | -5,362 | -15,416 | -27,306 | -23,795 | -20,486 |
| Interest Expense | 1,969 | 2,194 | 2,312 | 2,110 | 735 |
| Other Income | 5,414 | -2,758 | -3,607 | 6,050 | 4,529 |
| Pre-tax Income | -1,917 | -20,368 | -33,225 | -19,855 | -16,692 |
| Income Tax | 1,182 | 15,371 | N/A | 70 | -70 |
| Net Income Continuous | -3,099 | -35,739 | -33,225 | -19,925 | -16,622 |
| Net Income | $-3,099 | $-35,739 | $-33,225 | $-19,925 | $-16,622 |
| EPS Basic Total Ops | -0.06 | -0.71 | -0.69 | -0.48 | -0.40 |
| EPS Basic Continuous Ops | -0.06 | -0.71 | -0.70 | -0.48 | -0.40 |
| EPS Diluted Total Ops | -0.06 | -0.71 | -0.69 | -0.48 | -0.40 |
| EPS Diluted Continuous Ops | -0.06 | -0.71 | -0.70 | -0.48 | -0.40 |
| EPS Diluted Before Non-Recurring Items | -0.06 | -0.67 | -0.69 | N/A | N/A |
| EBITDA(a) | $-4,018 | $-14,658 | $-25,689 | $-22,233 | $-18,924 |